Form 8-K - Current report:
SEC Accession No. 0001193125-26-130419
Filing Date
2026-03-30
Accepted
2026-03-30 07:35:21
Documents
13
Period of Report
2026-03-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d118677d8k.htm   iXBRL 8-K 30782
2 EX-99.1 d118677dex991.htm EX-99.1 29860
  Complete submission text file 0001193125-26-130419.txt   237571

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA snse-20260330.xsd EX-101.SCH 3529
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE snse-20260330_def.xml EX-101.DEF 16182
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE snse-20260330_lab.xml EX-101.LAB 26682
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE snse-20260330_pre.xml EX-101.PRE 16870
17 EXTRACTED XBRL INSTANCE DOCUMENT d118677d8k_htm.xml XML 7616
Mailing Address 1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MD 20850
Business Address 1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MD 20850 (240) 243-8000
Sensei Biotherapeutics, Inc. (Filer) CIK: 0001829802 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39980 | Film No.: 26809988
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)